Business Context and Reporting Period
This Form 8-K Current Report was filed by Dare Bioscience, Inc. on July 4, 2023. The filing details a material definitive agreement entered into on the same date between Dare Bioscience and Organon International GmbH, an affiliate of Organon & Co.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. Specific financial impacts disclosed include:
- Immediate Payment: Organon will pay $1.0 million to Dare Bioscience to reimburse PDUFA fees and manufacturing expenses.
- Revised Milestone: The amount payable by Organon to Dare following the first commercial sale of a licensed product in the United States was revised to $1.8 million.
Material Changes
The primary material change is the amendment to the exclusive license agreement originally dated March 31, 2022. This amendment modifies the financial terms regarding reimbursement for regulatory and manufacturing costs and adjusts the milestone payment triggered by the first U.S. commercial sale.
Outlook, Risks, and Management Commentary
Commercial Outlook: Dare and Organon are working towards a U.S. launch of XACIATO in 2023 as soon as feasible. Additional manufacturing activities are underway to ensure supply continuity for the commercial launch.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Key risks include:
- Failure to achieve milestones under the Organon agreement.
- Dependence on Organon for commercialization and third parties for supply.
- Lack of control over third-party efforts and resources.
- Ability to raise additional capital to support operations and continue as a going concern.
- Macroeconomic factors such as inflation, rising interest rates, and geopolitical events.
Investor Verification Checklist
- Verify the full text of the Amendment to the license agreement, which Dare intends to file in its Form 10-Q for the period ending September 30, 2023.
- Confirm the timeline for the U.S. commercial launch of XACIATO and the status of manufacturing activities.
- Review Dare's recent Form 10-K and Form 10-Q filings for details on its liquidity position and ability to raise additional capital.
- Monitor the achievement of the revised $1.8 million milestone payment upon the first commercial sale.